Navigation Links
New Phase II study shows first-line promise of lung cancer drug PF-299
Date:10/12/2010

ollowed, the percentage of patients with EGFR mutations who are progression-free at six months is particularly promising, with 85% of patients remaining progression-free by nine months," Dr Mok said.

"We are excited by these encouraging early results, as they support our hypothesis that these next generation agents targeting multiple receptors on the HER pathway may offer an advantage," he said.

Dr Mok noted that in another study recently presented, PF299 was reported to be better than erlotinib in a randomized head-to-head Phase-II study in patients with advanced NSCLC who had progressed on at least one prior chemotherapy regimen.

"Our new results, even though preliminary, also suggest that PF-299 could offer an improvement over currently available options as a first-line treatment in both Asian and non-Asian patients with advanced NSCLC selected for likelihood of an EGFR activating mutation."

""The results of this trial are encouraging, particularly because 85% of EGFR-mutated patients treated with PF-299 as first-line remained progression-free at 9 months," commented Dr Enriqueta Felip, from Vall d'Hebron Hospital in Barcelona, Spain.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... DC (PRWEB) March 04, 2015 ... additional discussion leaders for its upcoming fifth annual ... in Paris, France. The event this year will ... more than 20 of the field’s leading companies ... bring together top executives and clinical researchers from ...
(Date:3/4/2015)... March 04, 2015 Jeannie Mai, TV personality, ... Real” graces the cover of the print publication. Mai embraces ... choose organic when shopping for clothes and personal care products. ... up about her commitment to an organic diet. She mentions, ... not only in gymnastics, but also now as I’m a ...
(Date:3/4/2015)... 2015 i2i Systems Population Health ... Chase Brexton Health Care, a 35-year-old Maryland-based community ... Brexton provides comprehensive primary care, behavioral health and ... seven clinics in the greater Baltimore area of ... records, the organization has always focused on providing ...
(Date:3/4/2015)... A new dieting routine, called the feast ... extending life. Studies conducted by the University ... can help extend life by increasing anti-oxidant production. While ... benefits, many suffering from obesity are already experiencing life ... As an alternative to the new Feast and Famine ...
(Date:3/4/2015)... Nitrosigine®, a patented complex of bonded arginine ... products, is hosting the Nitrosigine Pump Challenge at the ... at The Arnold Sports Festival in Columbus, Ohio. The ... 8, 2015. , Nitrosigine is a patented ingredient ... notification status; now affirmed as GRAS.^ It has been ...
Breaking Medicine News(10 mins):Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 3
... conference,focusing on the future of healthcare will convene ... Summit will present an opportunity for leaders from,around ... and future seismic,"tremors" in the healthcare industry in ... make the industry virtually unrecognizable in,the coming years., ...
... Corporation (Nasdaq: HLTH ) and its approximately 83% owned ... they will release,their respective financial results for the three months ... May 6, 2008. The Companies,will host a conference call at ... Investors can access the call via webcast at http://www.hlth.com ...
... Medicine Led by Simmons School for Health,Studies, BOSTON, ... (Dietary Approaches to Stop Hypertension), which is high in,fruits ... risk of coronary heart disease and stroke, according to ... Internal Medicine., The study indicates for the first ...
... amount had almost half the risk of needing to start ... with naturally high levels of the antioxidant urate in their ... than those with lower levels do, a new report says. ... Archives of Neurology , support early laboratory studies about ...
... DASH diet cuts cardiovascular risk, studies find , , MONDAY, ... additional benefits of widely used measures aimed at preventing ... the DASH diet for blood pressure control lowers the ... , The statin study wasn,t intended to measure the ...
... Americas Baby Boomer generation, arthritis is a growing ... common joint disease currently afflicts over 20 million ... aggravate matters, arthritis is also prevalent among the ... adult population. Fortunately, treating the pain and disability ...
Cached Medicine News:Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Risk of Women's Heart Attack or Stroke Appears to Be Lowered by 'DASH' Diet 2Health News:Elevated Urate Levels May Slow Parkinson's in Men 2Health News:New Benefits From Old Heart Measures 2Health News:New Benefits From Old Heart Measures 3Health News:Study shows increase of hip and knee replacements in the US 2Health News:Study shows increase of hip and knee replacements in the US 3
(Date:3/4/2015)... March 4, 2015 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... will participate in the upcoming 27 th Annual ... Dana Point, CA.  Dr. Michael ... Oramed, will present a corporate overview on March 10, ...
(Date:3/4/2015)... Mallinckrodt plc (NYSE: MNK ), a ... Global Healthcare Conference at the Loews Miami Hotel in ... 11, 2015. Mark Trudeau, President and Chief Executive Officer of ... to begin at 10:45 a.m. Eastern. Individuals ... webcast information on Mallinckrodt,s Investor Relations website ...
(Date:3/4/2015)... NEWARK, N.J. , March 4, 2015 /PRNewswire/ ... biopharmaceutical company developing innovative medicines for serious women,s ... 1 clinical program demonstrating that its lead product ... had predictable pharmacokinetics (PK), and that contraceptive efficacy ... by SYM-1219 administration. These results will ...
Breaking Medicine Technology:Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3Mallinckrodt to Present at Barclays Conference March 11 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5
... MedShape Solutions, Inc., the industry leader in innovative ... developed new, larger sizes of its ExoShape CL, ... simplifies and improves soft tissue graft fixation during ... comes after MedShape received the U.S. Food and ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced that ... the ongoing Phase Ia trial to test the safety of ... testing the drug in healthy volunteers for safety and tolerability. ... that stimulates new neuron growth in the hippocampus, an area ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
... the High Performance line, Zebra's 110XiIIIPlus is a ... hardworking printer is the one to call on ... available with either 4.09 inch (104 mm) or ... that best meets your needs, either 200, 300, ...
... tested XiIIIPlus platform, the R110Xifor four-inch ... on-demand printing flexibility in tag placement ... as XML for seamless integration into ... positioning, multiple power levels, statistics tracking, ...
... prints labels up to 8.5 ... It is ideal for wide ... chemical drum labels, primary metal ... banner-sized labels and pallet and ...
... CareChek Tx, which has received ... device for blood transfusions, allows ... patient to the unit of ... administering a transfusion.The system can ...
Medicine Products: